Cancer Genetics hopes to raise $6 million in an initial public offering. The Rutherford, N.J.-based company will use part of the proceeds to finance its joint initiative with the Mayo Foundation for Medical Education and Research to use advanced sequencing technology to develop cancer diagnostic tests and services.

Related Summaries